First author Under review
Open to fellowship & radionuclide-therapy posts
Dr. Mohit Seth
MBBS · DNB Nuclear Medicine
Precision oncology through theranostics — imaging and treating cancer with the same molecule.
22,000+PET-CT studies reported / workload
168¹⁷⁷Lu-PSMA therapies (mCRPC)
92PRRT ¹⁷⁷Lu-DOTATATE (NET)
255I-131 post-therapy scans
2,300+SPECT-CT gamma studies
About
A Nuclear Medicine physician trained where theranostics is practised at scale — using molecular imaging to find cancer and targeted radionuclides to treat it.
Dr. Mohit Seth completed his DNB in Nuclear Medicine (2023–2026) at Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Delhi — one of India's highest-volume theranostics centres. His practice spans the full precision-oncology pathway: Ga-68 PSMA, DOTANOC and FAPI PET/CT for staging, followed by ¹⁷⁷Lu-PSMA, ¹⁷⁷Lu-DOTATATE (PRRT) and I-131 radionuclide therapy, including hands-on management of inpatient therapy admissions.
He is first author on a prospective study of Ga-68 FAPI PET/CT in lung-cancer staging, presented orally at SNMMI 2025 in New Orleans, and is currently seeking an international fellowship in nuclear medicine and radionuclide therapy.
Expertise
Imaging and therapy, end to end
Diagnostic molecular imaging and the targeted radionuclide therapies that follow from it — the "see it, treat it" theranostics pairing, practised across a high-volume oncology service.
Radionuclide therapy
- 168 · ¹⁷⁷Lu-PSMA (mCRPC)
- 92 · ¹⁷⁷Lu-DOTATATE / PRRT (NET)
- 255 · I-131 post-therapy scans (thyroid Ca)
- I-131 mIBG · Y-90 radioembolisation
- Inpatient therapy admission & isolation
Molecular imaging (PET/CT)
- 22,000+ · PET-CT studies
- 18F-FDG · Ga-68 PSMA · Ga-68 DOTANOC
- Ga-68 FAPI · Ga-68 Trivehexin
- F-18 DOPA
- Staging, restaging & therapy response
Functional & SPECT studies
- 2,300+ · gamma / SPECT-CT studies
- Diuretic renography with GFR
- Hepatobiliary & future-remnant-liver volumetry
- Parathyroid · thyroid · bone · MUGA
- Salivary-gland scintigraphy
Research & Publications
Original work in FAPI & PSMA imaging
First-author research and case work at the frontier of theranostics imaging — with a focus on FAPI PET/CT and incidental findings on PSMA studies.
Case reports Submitted
Multiple oncology case reports on PSMA and FDG PET/CT findings
Several first-author case reports documenting incidental malignancies and atypical presentations on molecular imaging — submitted and awaiting publication.
Presentations & Awards
Presented & recognised
Oral presentation — SNMMI 2025, New Orleans
Ga-68 FAPI PET/CT in lung-cancer staging (in person, Jun 2025).
Poster — SNMMI Mid-Winter & ACNM 2026, Orlando
Incidental non-prostatic malignancies on Ga-68 PSMA PET/CT.
Posters — AOCNMB 2025, Chennai
FAPI PET/CT in lung cancer; FDG PET/CT in follicular lymphoma.
Poster — ANMPICON 2025, Hyderabad
Incidental esophageal NEC unmasked on PSMA PET/CT.
Best Resident Award — RGCIRC, 2025
Department of Nuclear Medicine.
2nd position — ANMPICON 2025 Quiz
National nuclear medicine quiz.
Education & Experience
Training & credentials
2023 — 2026
DNB, Nuclear Medicine
National Board of Examinations, New Delhi — trained at Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Rohini, Delhi.
DNB Reg. No. 124-20139-231-249153
2023 — present
DNB Resident, Nuclear Medicine — RGCIRC
High-volume theranostics and molecular imaging service; inpatient radionuclide therapy management.
2023
Delhi Medical Council — Registration
Registered medical practitioner, Delhi Medical Council.
Reg. No. 111664 · registered 12 Dec 2023
2023
Medical Officer — Narayan Seva Sansthan, Udaipur
High-volume OPD/IPD care (≈140+ patients/day), May–Oct 2023.
MBBS
Bachelor of Medicine & Surgery
RNT Medical College, Udaipur.
Let's talk
Open to fellowship and radionuclide-therapy positions. The fastest way to reach me is directly by email or phone.